USPTO Examiner VU JAKE MINH - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19066754MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESFebruary 2025August 2025Allow610NoNo
18906805METHOD FOR CONVERTING ATRIAL FIBRILLATION TO SINUS RHYTHM WITH LOW-RISK, LOW-COST PROTOCOL, AND PREVENTING RECURRENCE OF ATRIAL FIBRILLATIONOctober 2024October 2025Allow1311YesNo
18903882INJECTABLE FORMULATIONS OF PARP INHIBITORS AND USES THEREOFOctober 2024May 2025Allow721YesNo
18673805EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18673814EMBOLIC COMPOSITIONS AND METHODSMay 2024March 2025Allow1011NoNo
18648498COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD AND APPLICATION THEREOFApril 2024September 2024Allow501NoNo
18625862MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESApril 2024December 2024Allow810YesNo
18624706POLYOLS AND POLYOL-BASED HYDROGELS WITH ANTI-CANCER ACTIVITYApril 2024March 2025Allow1131NoNo
18615185LIQUID DOSAGE FORMS OF SODIUM NAPROXENMarch 2024March 2026Abandon2401NoNo
18408490MODIFIED RELEASE NICORANDIL COMPOUND FORMULATIONSJanuary 2024December 2024Abandon1201NoNo
18567702CARBOXYLIC ACID LOADED SALT CARRIER AND THE METHOD FOR PRODUCING THEREOFDecember 2023September 2025Allow2121NoNo
18527781HYDROCOLLOID-BASED SKIN PATCHDecember 2023July 2025Abandon2021NoNo
18526225Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrileDecember 2023August 2024Allow900NoNo
18513856STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTIONNovember 2023February 2026Allow2721NoNo
18374645COMPOSITIONS COMPRISING A THERMOREVERSIBLE HYDROGEL, AND HAVING AN EXTENDED IN-USE PERIODSeptember 2023July 2024Abandon1001NoNo
18354636Hydrogel Particle Encapsulated Viable Cells for In Vivo Regenerative TreatmentJuly 2023December 2025Allow2821YesNo
18129508MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESMarch 2023May 2024Abandon1411NoNo
18129543MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESMarch 2023March 2024Abandon1101NoNo
18129497MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESMarch 2023November 2024Abandon1921NoNo
18187248METHOD OF IMAGINGMarch 2023June 2025Allow2731YesNo
18187244METHOD OF MANUFACTURING AN EMBOLIZING AGENT PRECURSORMarch 2023December 2024Abandon2121YesNo
18187264METHOD OF USING HIGH-FREQUENCY SOUND WAVESMarch 2023June 2025Allow6031YesNo
18187413EMBOLIZING AGENT PRECURSOR PHARMACEUTICAL COMPOSITIONMarch 2023May 2024Abandon1411NoNo
18118212TOPICAL ANALGESIC GEL COMPOSITIONSMarch 2023November 2025Allow3220NoNo
18118472METHOD FOR PRODUCING ORGANIC MATERIAL MICROPARTICLES, AND METHOD FOR MODIFYING ORGANIC MATERIAL MICROPARTICLESMarch 2023February 2026Abandon3630NoNo
18040585BACTROCERA OLEAE ATTRACTANT COMPOSITION AND USES THEREOFFebruary 2023June 2025Allow2811NoNo
18159860PHOTOTHERMAL NANOSTRUCTURES IN TUMOR THERAPYJanuary 2023May 2025Abandon2820YesNo
18094673MEDICAL DEVICE FOR DELIVERY OF LIFTING AGENTJanuary 2023May 2025Abandon2821NoNo
18093554LIPID EMULSIONS AND USES THEREOFJanuary 2023February 2026Allow3751YesYes
18086412Improved SupraparticlesDecember 2022May 2025Abandon2821YesNo
18085372SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSISDecember 2022May 2025Abandon2921NoNo
17999969APPLICATION OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING DISEASE RELATED TO THYROIDECTOMYNovember 2022February 2026Allow3910NoNo
17997347METHOD FOR DECOMPOSING COMPOUND AND COMPOUNDOctober 2022February 2026Abandon3901NoNo
17930169PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIASeptember 2022September 2025Abandon3621YesYes
17821680STARCH-FREE SOFT CHEW FOR VETERINARY APPLICATIONSAugust 2022March 2023Allow710NoNo
17751924COMPOSITIONS AND ARTICLES COMPRISING (NANO)DIAMOND PARTICLESMay 2022August 2025Abandon3941NoYes
17745428Dry Powder Formulations for Messenger RNAMay 2022December 2025Allow4331NoNo
17727680TREATMENTS FOR BENIGN PROSTATIC HYPERPLASIAApril 2022December 2023Allow2031YesNo
17722986WOUND DRESSING COMPRISING AN ANTIMICROBIAL COMPOSITIONApril 2022August 2025Allow4031NoNo
17723013SILICONE-BASED ENTERIC CT CONTRAST MATERIALApril 2022August 2025Allow4021YesYes
17715491STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTIONApril 2022August 2023Allow1721YesNo
17634764ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-I LIKE PROTEIN (OMCP) FOR TREATMENT OF AUTOIMMUNE DISEASEFebruary 2022September 2025Abandon4301NoNo
17632568PERIVASCULAR LYSATES AND USES THEREOFFebruary 2022November 2025Abandon4601NoNo
17625705MULTIVESICULAR LIPOSOME FORMULATIONS OF DEXMEDETOMIDINEJanuary 2022February 2026Abandon4911NoNo
17569720REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOFJanuary 2022November 2024Abandon3411NoNo
17566882MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESDecember 2021January 2024Abandon2511NoNo
17539445MEDICAL DEVICE FOR DELIVERY OF INJECTABLE GEL AND METHODS OF FORMING SAMEDecember 2021October 2025Abandon4721NoYes
17520800TOPICAL DOXYCYCLINE HYDROGEL WITH IMPROVED LONG-TERM STABILITYNovember 2021February 2022Allow300NoNo
17506051Medical Device for Delivery of Lifting AgentOctober 2021March 2023Abandon1721NoNo
17604659HYDROGEL DRUG DELIVERY COMPOSITIONOctober 2021May 2025Allow4331YesNo
17492328PATIENT SELECTION METHOD FOR INFLAMMATIONOctober 2021February 2026Abandon5331NoNo
17489982MEDROXYPROGESTERONE ACETATE INJECTABLE COMPOSITIONS AND METHODS OF USESeptember 2021October 2023Allow2520NoYes
17599379TARGETING COMPOUNDS FOR CANCERS SELECTED FROM ESOPHAGUS, PHARYNX AND LARYNX, LUNG, BRAIN, AND INTESTINESSeptember 2021June 2025Abandon4501NoNo
17473590ENCAPSULATED GAS OR PARTIAL VACUUM CT CONTRAST MATERIALSeptember 2021September 2024Allow3621YesYes
17472541CHLOROQUINE GEL AND PREPARATION METHOD AND APPLICATION THEREOFSeptember 2021December 2022Allow1500NoNo
17469012TOPICAL COMPOSITIONS AND METHODS OF USESeptember 2021September 2025Allow4841YesNo
17433736DYNAMIC COVALENTLY LINKED HYDROGELS AS STABILIZATION NETWORK PLATFORMSAugust 2021January 2024Abandon2911NoNo
17412231Therapeutic Medical Device and Methods of UseAugust 2021December 2023Abandon2721NoNo
17433267OPTICALLY HEAT-GENERATING COMPOSITE MATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER AND PHARMACEUTICAL COMPOSITIONAugust 2021March 2026Abandon5421NoNo
17431405HIGH YIELD PRODUCTION OF MICROBUBBLESAugust 2021February 2026Abandon5421NoNo
17401589COMPOSITIONS AND THERAPIES USING NANODIAMONDS SUSPENDED IN A CARRIERAugust 2021June 2024Allow3401YesNo
17430683CT CONTRAST AGENT FOR DETECTION OF CACHEXIAAugust 2021June 2025Allow4611YesNo
17389936INVISIBLE SINGLET FILMJuly 2021December 2023Abandon2931NoNo
17425699CONTRAST SOLUTION FOR THE CHARACTERISATION OF BIOLOGICAL SAMPLES BY ELECTRON OR CORRELATIVE MICROSCOPYJuly 2021October 2025Abandon5111NoNo
17425430SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOFJuly 2021November 2025Allow5121NoNo
17424616ALBUMIN NANOPARTICLES, THE MAKING METHOD, AND USES THEREOFJuly 2021December 2024Abandon4101NoNo
17374564LIQUID DOSAGE FORMS OF SODIUM NAPROXENJuly 2021April 2024Abandon3321NoNo
17418704METHOD FOR PRODUCING NANOPARTICLE HAVING METAL PARTICLE WHICH CONTAINS IRON OXIDE TO WHICH ONE OR MORE HYDROPHILIC LIGANDS ARE COORDINATION BONDEDJune 2021February 2025Abandon4301NoNo
17418120Methods for Imaging and Treatment of Somatostatin-Receptor Positive TumorsJune 2021March 2025Allow4511YesNo
17413923TERNARY MICELLAR COMPLEX COMPOSED OF A SIALOGLYCOSPHINGOLIPID, A THERAPEUTICALLY ACTIVE SUBSTANCE AND AN ANTIBODYJune 2021December 2024Abandon4201NoNo
17342945EMBOLIC COMPOSITIONS AND METHODSJune 2021April 2024Allow3421YesYes
17296187Self-Assembled Microcapsules With Stimuli-Responsive Organic LigandsMay 2021November 2024Allow4121YesNo
17325290THERMOSENSITIVE HYDROGEL FOR CANCER THERAPEUTICS AND METHODS OF PREPARATION THEREOFMay 2021December 2023Allow3111YesNo
17302917ULTRASOUND MEDIATED DELIVERY OF DRUGSMay 2021May 2025Allow4841YesYes
17313136COMPOSITIONS COMPRISING TAPINAROF FOR THE TREATMENT OF PRURITISMay 2021June 2023Abandon2501NoNo
17291996METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGESMay 2021March 2025Allow4711YesNo
17246852TRANSMUCOSAL DRUG DELIVERY SYSTEMMay 2021June 2023Abandon2501NoNo
17306482Implantable Embolic Scaffolds That Promote HealingMay 2021October 2024Abandon4121NoNo
17287692MARKING PRECURSOR WITH SQUARIC ACID COUPLINGApril 2021April 2025Allow4711YesNo
17227024COMBINATION THERAPY FOR TREATING METASTATIC PROSTATE CANCERApril 2021May 2025Abandon4911NoNo
17280735METHOD FOR OBTAINING CONDITIONED FISH MODELSMarch 2021June 2025Abandon5121NoNo
17279504Imaging Agents and Methods of UseMarch 2021August 2024Abandon4101NoNo
17207226Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body FluidsMarch 2021November 2024Abandon4301NoNo
17206979METHOD FOR PREPARING FLUORINE-18-LABELED FLUOROMETHYL-SUBSTITUTED RADIOPHARMACEUTICALS USING SELECTIVE AZIDE SUBSTITUTION REACTION AND PRECURSOR SCAVENGINGMarch 2021October 2024Allow4311YesNo
17272607POROUS BIORESORBABLE RADIOPAQUE EMBOLIC MICROSPHERES FOR DRUG DELIVERYMarch 2021February 2025Allow4831YesNo
17270268METHOD FOR PREPARING GADOBUTROLFebruary 2021October 2024Allow4410NoNo
17269094PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORSFebruary 2021July 2024Abandon4101NoNo
17267788MEDICAL HYDROGELFebruary 2021June 2025Abandon5241NoNo
17266922METHODS FOR DISEASE TREATMENT AND DRUG DISCOVERYFebruary 2021August 2025Allow5511NoNo
17266190CONJUGATE OF BIOTIN-MODIFIED DIMER AND PHTHALOCYANINE DYEFebruary 2021June 2025Abandon5321NoNo
17266549NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATIONFebruary 2021August 2024Abandon4221NoNo
17264716DENDRITIC NANOGEL CARRIERS AND METHOD OF PRODUCTIONJanuary 2021February 2024Allow3721YesNo
17160265OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORINJanuary 2021December 2021Abandon1001NoNo
17160252Method of treating ophthalmic conditionsJanuary 2021June 2023Abandon2810NoNo
17160258METHOD OF TREATING OPHTHALMIC CONDITIONSJanuary 2021June 2023Abandon2810NoNo
17160261METHOD OF TREATING OPHTHALMIC CONDITIONSJanuary 2021June 2023Abandon2810NoNo
17160264METHOD OF TREATING OPHTHALMIC CONDITIONSJanuary 2021June 2023Abandon2810NoNo
17160272METHOD OF TREATING OPHTHALMIC CONDITIONSJanuary 2021June 2023Abandon2910NoNo
17160270OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORINJanuary 2021January 2022Abandon1101NoNo
17152649METHOD OF TREATING OPHTHALMIC CONDITIONSJanuary 2021October 2021Abandon901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VU, JAKE MINH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
78
Examiner Affirmed
55
(70.5%)
Examiner Reversed
23
(29.5%)
Reversal Percentile
46.1%
Lower than average

What This Means

With a 29.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
214
Allowed After Appeal Filing
38
(17.8%)
Not Allowed After Appeal Filing
176
(82.2%)
Filing Benefit Percentile
21.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner VU, JAKE MINH - Prosecution Strategy Guide

Executive Summary

Examiner VU, JAKE MINH works in Art Unit 1618 and has examined 953 patent applications in our dataset. With an allowance rate of 35.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner VU, JAKE MINH's allowance rate of 35.8% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by VU, JAKE MINH receive 2.81 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by VU, JAKE MINH is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +34.9% benefit to allowance rate for applications examined by VU, JAKE MINH. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.9% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.8% of cases where such amendments are filed. This entry rate is in the 21% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 53.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 46.9% of appeals filed. This is in the 12% percentile among all examiners. Of these withdrawals, 49.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.8% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.